Understand Pathogenesis, Analyze Fibrotic Progression & Navigate Clinical Drug Development to Accelerate Antifibrotic Effect for Progressive Fibrotic ILDs
With the entire world’s attention focused firmly on pulmonary fibrosis in the wake of COVID19 and the landmark INBUILD study dramatically overhauling the ILD drug development landscape, biopharma are finally on the cusp of developing and disseminating life-changing therapeutics for patients suffering with interstitial lung disease.
Built from meticulous research with a faculty of world-renowned lung fibrosis heavyweights including Boehringer Ingelheim, Novartis, Roche, Abbvie, AdAlta and more, the inaugural Interstitial Lung Disease Drug Development Summit is the only industry focused forum giving you access to the ground-breaking research and radical insights you need to re-energize and revolutionize your drug development strategy against the next pulmonary fibrosis frontier.
Across 3 unique days, you will discover how to optimize combination regimes to treat fibrotic lungs to achieve success in your clinical trials, analyze lessons learned from IPF trials to accelerate progress for your novel pulmonary fibrosis therapies and hear how you can utilize the latest research on ILD mechanisms to streamline your drug development strategy and treat SSc-ILD, RA-ILD, Scleroderma, Sjogren’s Syndrome, Sarcoidosis and more.
Don’t miss the opportunity to join 50+ senior respiratory and fibrosis stakeholders at this unique and comprehensive digital event dedicated to advancing and optimizing your anti-fibrotic drug development beyond IPF
World Class Speaker Faculty Included:
Medical Expert ILD Respiratory Clinical Development & Medical Affairs
University of Michigan
Professor &Chair, Department of Medicine
National Jewish Health